Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function

Area of Science:

• Pediatric Respiratory Medicine
• Infectious Diseases
• Pulmonary Function Testing

Background:

• Mycoplasma pneumoniae is a common respiratory pathogen in children.
• The long-term respiratory sequelae of Mycoplasma pneumoniae infection are not fully understood.
• Wheezing is a frequent symptom during acute Mycoplasma pneumoniae infections.

Purpose of the Study:

• To assess the incidence and persistence of wheezing following Mycoplasma pneumoniae infection in children.
• To evaluate bronchodilator responsiveness and pulmonary function changes one month and three years post-infection.
• To investigate the effect of early erythromycin treatment on fever duration and long-term outcomes.

Main Methods:

• Prospective study of 108 children with Mycoplasma pneumoniae infection.
• Assessment of wheezing, bronchodilator responsiveness, and pulmonary function (including FEV1 and FEF50) during acute illness and at 3-year follow-up.
• Comparison with 64 healthy controls and analysis of treatment effects.

Main Results:

• 40% of children experienced wheezing during acute Mycoplasma pneumoniae infection.
• Non-asthmatic children showed significant bronchodilator responsiveness one month post-infection.
• Three years later, non-asthmatic children exhibited abnormal mean forced expiratory volume in one second (FEV1) and forced expiratory flow after 50% of the expired vital capacity (FEF50) compared to controls.

Conclusions:

• Mycoplasma pneumoniae infection can precipitate new-onset wheezing or exacerbate existing conditions.
• Impaired pulmonary function, specifically reduced FEV1 and FEF50, can persist for at least three years after Mycoplasma pneumoniae infection in non-asthmatic children.
• Early erythromycin treatment shortened fever duration but did not significantly impact long-term pulmonary function.